1	Topical application of Urolithin A slows intrinsic skin aging and protects from
2	UVB-mediated photodamage: Findings from Randomized Clinical Trials
3	
4	
5	
6	D'Amico D <sup>1</sup> , Fouassier AM <sup>1</sup> , Faitg J <sup>1</sup> , Hennighausen N <sup>2</sup> , Brandt M <sup>2</sup> , Konstantopoulos D <sup>3</sup> ,
7	Rinsch C <sup>1</sup> , Singh $A^{1\dagger}$
8	
9	
10	
11	
12	<sup>1</sup> Amazentis SA, EPFL Innovation Park, 1015 Lausanne, Switzerland
13	<sup>2</sup> SGS Proderm GmbH, Hamburg, Germany
14	<sup>3</sup> Genevia Technologies OY, 33100 Tampere, Finland
15	
10	
10	
17	
18	<sup>†</sup> Correspondence: <u>asingh@amazentis.com</u>
19	
20	
21	
22	
23	

## 24 Abstract

25 Urolithin A is a gut microbiome derived postbiotic that has been shown to stimulate mitophagy, 26 and improve muscle and mitochondrial health when administered orally to humans. In three 27 separate randomized trials, we have now investigated the effect of topical administration of 28 Urolithin A on skin aging features and on UVB-mediated photodamaged skin. Post-menopausal women with evidence of skin aging such as > Grade 3 wrinkle formation were included in a 29 30 split-face/arm study design in the first trial (aging study 1; n=48), followed by a second larger 31 trial (aging study 2; n=108) in middle-aged men and women focusing on wrinkle reduction. 32 Healthy participants were included in the placebo-controlled, randomized UVB-induced trial 33 (*photo-damage trial*; n=22). Participants were randomized to receive topical supplementation 34 with either 0.5% Urolithin A cream or placebo for 8-weeks in a low-dose arm or 1% Urolithin A 35 cream or placebo in the high-dose arm in the aging study 1. In the aging study 2 participants 36 were randomized to receive 1% UA in a day-cream, a night cream and a serum, that were 37 compared to the untreated site. For the *photo-damage trial*, topical patches containing either 0.5% 38 or 1% UA or placebo cream were applied for 24-hours following UVB irradiation. The primary 39 outcome in the *aging study 1* was an impact on biological pathways linked to skin aging in skin biopsies, and an impact on skin barrier function after 8-weeks. Key secondary endpoints were a 40 41 change in facial wrinkle appearance (crow's feet area). The aging study 2 focused on wrinkle 42 reduction as a primary outcome. In the UVB-mediated *photo-damage study*, the primary read-out 43 was the change in erythema after application. Molecular analyses were conducted on skin biopsies and using ex-vivo systems to investigate the mechanism of action mediating skin 44 45 protective effects of Urolithin A. In the aging study 1, Urolithin A at 1% significantly upregulated collagen synthesis pathways in human skin biopsies and led to a decrease in wrinkle 46 47 depth on facial wrinkles. The lower dose had no significant impact. There was no change on skin 48 barrier function with both doses suggesting maintenance of a healthy skin barrier function. In 49 aging study 2, topical application of Urolithin A at the 1% dose in different formulations (daycream, night cream and serum) led to significant wrinkle reduction compared to the untreated 50 side, confirming the previous findings. Skin hydration was improved significantly as well. In the 51 52 third trial, investigating impact on photodamaged skin, Urolithin A application led to a 53 significant decrease in UV-induced erythema (~14%) compared to the untreated area, while

54	placebo and lower dose UA cream's showed no benefits. Urolithin A topical administration was
55	safe and well-tolerated in all studies. UA also inhibited collagen degrading and pro-
56	inflammatory pathways and up-regulated gene expression of biomarkers linked to induction of
57	mitophagy and autophagy in human skin cells. Taken together, these clinical studies support the
58	topical use of Urolithin A to manage and prolong skin health longevity by acting at the cellular
59	level, supporting collagen structure, reducing wrinkle appearance and protecting against
60	photoaging.
61	
62	The studies are registered in clinicaltrials.gov as: NCT05300984; NCT05473832; NCT05300542
63	
64	
65	
66	
67	
68	
69	
70	
71	
72	
73	
74	
75	
76 77	
70	
/ð 70	
80	
00	

## 82 Introduction

83 Skin is the largest organ in the body and serves key functions as a barrier against injuries, UV 84 light and pathogens. Chronological aging brings changes in skin appearance and a decline in its protective functions. This is further accentuated following exposure to UV radiation, by a 85 process called photoaging<sup>1</sup>. The most common signs of aging skin are the appearance of wrinkles, 86 87 skin thinning, hyperpigmentation, sagginess, and dryness. This derives from a combination of 88 biological changes, including a decline in quantity and quality of structural components of the 89 skin, such as collagen and elastin, as well as dysfunctions in cellular bioenergetics. Indeed, most 90 of the energy to support skin cell heath is derived from mitochondria, making mitochondrial dysfunction a key hallmark of skin aging <sup>2,3</sup>. Finally, immune cells located in the skin are 91 92 impacted by the aging process. This reduces the ability of the skin to cope with excessive 93 inflammation by external agents and significantly contributes to the emergence of photoaging<sup>4</sup>.

94

95 Current approaches to counteract skin aging are limited and primarily include retinol or retinoid-96 based solutions. They are effective, for example, at wrinkle reduction, but do not have the best safety and tolerability profile and are controversial in the management of photoaging<sup>5,6</sup>. There is 97 98 a need for new innovative natural bioactives for improving skin health and longevity, that have a 99 dual benefit profile, impacting both intrinsic and extrinsic aging, without irritations observed with retinol and retinoids. Urolithin A (UA) is a food metabolite, and a postbiotic of the gut 100 101 microbiome that has been shown to both improve mitochondrial health and reduce age-102 associated inflammation, i.e. inflamm-aging. UA increases mitophagy, the process of recycling 103 faulty mitochondria, and enhances biomarkers associated with better mitochondrial function in several models of aging and age-associated conditions<sup>7</sup>. In humans, oral supplementation of UA 104 105 was shown to be safe, improve mitochondrial function, and improve muscle strength and endurance in clinical studies in middle-aged and elderly subjects<sup>8,9</sup>. 106

107

108 Topical application of UA represents a promising strategy to support skin health and extend skin 109 longevity through its combined effect on multiple hallmarks of skin aging. We performed a 110 systematic clinical investigation of the benefits of topical application of UA to investigate its 111 safety and impact on clinical readouts of both intrinsic skin aging and photoaging. Finally, we

- analysed skin biopsies and human cell models to identify molecular mechanisms associated with
- 113 UA's protective effect on the skin tissue.
- 114
- 115
- 116
- 117

## 118 Methods

Subject recruitment: All the studies were approved by an independent institutional review 119 120 board (Institutional Review Board, proderm GmbH, Kiebitzweg 2, D-22869 Schenefeld, 121 Germany). The subjects were recruited at the study site for each of the studies (SGS Proderm, 122 Hamburg, Germany). The suitability of each subject was evaluated according to the various 123 inclusion and exclusion criteria. Subjects gave written informed consent to participate in the study and to come to the scheduled visits. In the first aging study (aging study 1) only female 124 125 participants from 50 to 75 years of age with visible wrinkle in the face (grade 3 to 6 according to 126 wrinkle severity scale) were included. In the second aging study (aging study 2), both males and 127 females from 40 to 65 years of age were recruited with similar criteria as the first study. Subjects 128 had healthy skin in the test areas. Prior/concomitant diagnoses and prior/concomitant therapies 129 relevant for the study were recorded. Main exclusion criteria were any documented allergies to 130 cosmetic products and/or ingredients, skin care and/or skin cleansing products and use of any 131 topical medication at the test area within the last 3 days prior to the start of the study. For the 132 photodamage study, both females and male participants from 18 to 65 years of age were included. 133 Subjects had uniform skin color and no erythema or dark pigmentation in the test area prior to 134 the start of the study. The skin type of the enrolled subjects was classified by use of colorimetric 135 skin type classification.

#### 137 Randomization and instructions of use:

138 The skin aging studies both followed the split-face study design, i.e., each participant was 139 randomly assigned to the test products to apply on either the left or the right side of the face and 140 arm in case of the first study where skin biopsies were collected. All studies were controlled, 141 randomized studies with the first aging and UVB erythema trial also being double-blind, 142 placebo-controlled studies. The second aging trial utilized a split-face design with a treated and an untreated side for comparison. The tested products were the following for the both the aging 143 144 study 1 and the photodamage study: a moisturizing skin base cream containing standardized excipients (vehicle) and for the (active) arms containing either 0.5 or 1% UA (Mitopure<sup>TM</sup>) 145 added in the base cream. The products tested in the aging study 2 contained 1% UA (Mitopure<sup>TM</sup>) 146 147 in a day-cream formulation, a night-cream formulation and a serum product. A study site 148 representative assigned test products so that both the subjects and the investigators were blinded 149 to the test article identification. The information containing the assignment of products to labels 150 was kept at the study site by a person not involved in the investigations and analysis of data 151 during the study. Statistical analyses plan was finalized before unblinding. Afterwards the 152 envelope with the assignment of codes to treatments was opened to unblind the study for analysis. 153 A study technician demonstrated to study participants the correct amount of the test product to be 154 applied during the first application. The test materials were applied twice daily in the morning 155 and evening for 8-weeks by the subjects at home according to the application training in the first 156 aging study, whereas in the second trial subjects applied it either in the day (for day-cream) or 157 the evening (for night-cream), or twice daily in the morning and evening for serum. The subjects 158 were instructed to use the test product every day.

159

160 Skin barrier function was quantified as transepidermal water loss (TEWL) and was measured 161 via a TEWAMETER® TM 300 (Courage & Khazaka, Cologne, Germany). TEWL is a non-162 invasive method to measure the barrier function of the skin and is regarded as a sensitive 163 parameter to quantify skin barrier damage. One measurement per test area and assessment time 164 was recorded. Briefly, water evaporation from the skin was measured by placing cylindric open 165 chamber with two hygrosensors at a defined distance from the skin. The probe was held in place

166 for each measurement for 30 seconds. The values of the last 10 seconds (= 10 values) were
167 averaged as the actual measurement value.

168

169 Skin roughness and wrinkle assessment was performed either via a DERMATOP blue (Eo 170 Tech SA, Marcoussis, France) in aging study 2 or via standardized, computer-controlled facial 171 photography with a 24 Megapixel Nikon camera (Colorface<sup>®</sup>, Newtone Technologies, Lyon, 172 France) in aging study 1. The anti-wrinkle efficacy of each treatment code was assessed in the periorbital regions by investigating the three-dimensional structure of the wrinkles. These 173 174 assessments were conducted at 2 and 8 weeks in the first aging study and at 2, 4 and 8 weeks in the second study. Using phase-shifted and gray-coded measurements of human skin the three-175 176 dimensional surface structure of the investigated skin site was captured. The measuring principle 177 is based on digital fringe projection. The fringes that are projected under a defined triangulation 178 angle onto the surface of the measured target with a sinus-like intensity of brightness are 179 detected with a CCD camera. The three-dimensional skin surface profile is calculated from the position of the fringes in combination with the gray values of each pixel. From the captured 180 181 three-dimensional structure, roughness parameters are calculated. Parameters: Rz and Ra are 182 chosen, representing mainly the rough structure (Rz) or the finer skin structure (Ra). A decrease 183 in the roughness parameters Rz and Ra corresponds to a decrease in the degree of skin roughness. 184 1 measurement per test area and assessment time was performed.

185

186 Skin hydration assessment was measured via the CORNEOMETER CM 825 (Courage & 187 Khazaka, Cologne, Germany). The measurement of stratum corneum hydration was performed 188 by the electrical capacitance method with the corneometer. The measuring principle is based on 189 changes in the capacitance of the measuring head, functioning as a capacitor. Between the 190 conductors consisting of gold, an electrical field is built. By these means, the dielectricity of the 191 upper skin layer is measured. Because the dielectricity varies as a function of the skin's water 192 content, the stratum corneum hydration can be measured. Five measurements per test area and 193 assessment time were performed and the average recording used for statistical analysis.

194

195 Skin biopsy excision (from *aging study 1*): The room and biopsy area (dorsal forearms) were
196 disinfected prior to the procedure with the disinfectant spray (e.g. Octenisept®). A local

197 anesthetic (e.g. Skandicain® 1%) was administered to the biopsy site subcutaneously using a 198 sterile syringe, fitted with a suitable sterile needle, to the biopsy area prior to excision of the 199 biopsy. Punch biopsies (3-mm) were be sampled by a physician using a punch biopsy instrument. 200 The biopsy specimen contained the epidermis and the dermis. Each biopsy sample was then 201 appropriately labelled (with the study and subject number). Following the biopsy excision, the 202 wound was closed with SteriStrips<sup>®</sup> and covered with a protective dressing. The subjects were 203 supplied with waterproof dressings for covering the wounds after skin biopsies were taken. The 204 wounds had to be kept dry until the wounds healed. Instructions on changing the dressing and 205 spare dressings were provided to the subjects. In order to reduce the risk of hyperpigmentation 206 the participant's undergoing skin biopsy procedure were instructed to avoid sunlight at the test 207 areas after conduct of the study and/or to use a sun protection cream. Biopsies were collected at 208 baseline and end of the study.

209

210 MED dose calculation, UVB erythema induction and assessments: A solar simulator 211 multiport 300 W (SOLAR Light Co, Philadelphia, USA) lamp equipped with appropriate 212 filtration was used to irradiate the skin test areas with the requested irradiation intensity on spots 213 with a diameter of 1 cm. A single irradiation per test area was performed. Test areas were 214 outlined with a skin marker on the backs of the subjects. Thereafter, baseline measurements were 215 performed on all test areas. After that six spots for minimal erythema dose (MED) determination were irradiated on the back with a diameter of 0.9 cm each. The UVB dose was increased from 216 217 spot to spot by an increment of 25 %. An untreated irradiated control area served as a negative 218 control. After irradiation, the test products were applied using an occlusive patch to the irradiated 219 spots post irradiation.  $23 \pm 2$  hours after irradiation, subjects returned to the study site and 220 product topical patches were removed. Residues of the test products were carefully removed with 221 a dry soft paper tissue. The MED dose and a change in skin redness (erythema score) from 222 baseline was recorded via a CHROMAMETER CR 400 (Minolta, Device D-Langenhagen, 223 Germany). The Chromameter defines the measured color in the L\*a\*b\* color coordinate system. 224 The L\*-value defines the brightness. The color is defined by the parameters a\* (red-green axis; 225 negative a\*-value green, positive a\*-value red) and b\* (blue-yellow axis, negative b\*-value blue, 226 positive b\*-value yellow). The a\* value correlates well with visual assessments of skin redness 227 (erythema). a\* is a measure for erythema. An increase in the a\*-value corresponds to an increase

in the degree of skin redness. A trained grader also assessed the skin erythema for each group of
irradiation dose of the different test areas, according to the following scale: -2=marked increase
in redness compared to negative control (untreated); -1 =slight increase in redness compared
to negative control (untreated); 0=no difference in redness compared to negative control
(untreated) (no effect); 1=slight decrease in redness compared to negative control (untreated);
2=marked decrease in redness compared to negative control (untreated);
2=marked decrease in redness compared to negative control (untreated);
of redness.

235

Adverse reactions recording: All ICH GCP guidelines of recording of adverse reactions (ARs) were followed. For all the clinical studies all ARs were assessed by the study physician for a causal relationship between the test material and the adverse event (AE) was established. All adverse reactions (excluding those parameters being scored as part of the protocol) were documented in the study records. ARs were recorded from study enrolment of the subject in a study to until 5 days following last administration of test product.

242

#### 243 RNA-seq

244 Skin tissue samples were disrupted in a TissueLyser and RNA extraction performed using an 245 automated QiaSymphony extraction robot and the QIAsymphony RNA Kit. Strand-specific 246 cDNA library preparation was performed by purification of poly-A containing mRNA molecules, 247 mRNA fragmentation, random primed cDNA synthesis (strand-specific), adapter ligation and 248 adapter specific PCR amplification. RNA-seq run was performed using the NovaSeq6000 using 249 S4 flowcells with 2x150bp. Quality Control (QC) and preprocessing of raw reads was performed 250 by an in-house QC pipeline. The pipeline utilizes fastP version 0.23.2 [Chen, 2018], for quality 251 control, quality trimming, and adapter clipping procedures. Reads with a minimum PHRED 252 score of 15, a minimum length of 15 bp, and a minimum ungualified percent limit of 40 (40%) 253 were retained for downstream analysis. QC reports were summarized by MultiQC version 1.12 254 [Ewels et al., 2016]. Quality-processed read pairs were mapped against the Ensembl human 255 reference genome GRCh38.99, using a transcriptome annotation GTF file (version GRCh38.105). 256 In particular, an in-house RNA-sequencing alignment pipeline that utilizes the STAR algorithm 257 version 2.6.1c [Dobin et al., 2013] was applied. Read counting was performed on the gene-level,

258 using htseq-count [Putri, 2022]. To inspect the alignment results, MultiOC was used accordingly. 259 Read counts were normalized to account for inherent compositional and technical biases using 260 "median of ratios" [Anders and Huber, 2010] method from DESeq2 R package [Love, 2014]. 261 Differential expression analysis was applied for Mitopure condition, controlling by vehicle 262 condition, and by comparing samples between two visits (T2 vs T1), adjusting the DESeq2 263 design formula accordingly (design =  $\sim$  Treatment + visit + Treatment: visit). Before DEA, a 264 pre-filtering step was applied to remove low abundance mRNA measurements, by excluding 265 genes with less than 10 total counts across samples. Additionally, an independent filtering 266 procedure of DESeq2 was enabled, to filter out genes with very low counts that are unlikely to 267 show significant alterations in gene expression. Gene symbols (HGNC nomenclature), 268 descriptions, and biotypes were matched to Ensembl GTF ids by using the R package biomaRt. v. 269 2.46.3 [Durinck et al., 2009]. P-values were corrected for multiple-testing using the Benjamini 270 and Hochberg (BH) method [Benjamini and Hochberg, 1995].

271

#### 272 Gene Set Enrichment Analysis

Gene Set Enrichment Analysis (GSEA)<sup>10</sup> was performed by using the R package ClusterProfiler 273 <sup>11</sup>. All processed and filtered genes (genes with at least 10 total counts across samples having an 274 275 applicable p-adjusted value) were ranked by the comparison's log2 fold change, and the 276 enrichment of a given gene set among "activated"- or-"suppressed" genes was statistically tested. Gene sets from ontologies within Gene Ontology (GO)<sup>12</sup> Biological Processes (BPs) were 277 278 tested. The minimum and maximum gene set sizes were set to 10 and 500, respectively. The 279 resulting p-values were adjusted using the BH method. Enriched terms with a maximum adjusted p-value of 0.05 were considered statistically significant. GSEA significant results were 280 visualized as dot plots using the enrichplot R package <sup>11</sup>. Expression changes of core enrichment 281 282 genes of significant GO BP terms for the "Mitopure normalized over vehicle" comparison was 283 further visualized. For the particular analysis, only subjects present in both visits (T1 and T2) 284 and both treatments (Mitopure and vehicle) were considered. Initially, for each treatment, each 285 subject's T2 expression values were corrected by their corresponding T1 expression. Then, 286 Mitopure expression changes were further corrected by the vehicle expression changes, between 287 the respective subjects. Ratios are referred as "Fold changes over vehicle". Finally, log2 Fold

changes over vehicle were visualized as heatmaps, by utilizing pheatmap R package [Kolde,
2018]. Genes were hierarchically clustered with a euclidean distance metric using complete
linkage.

291

#### 292 Skin aging dataset analysis

293 A text file depicting gene expression changes with age in skin was retrieved by the supplemental material of a previously published study <sup>13</sup>. The particular dataset was reanalyzed by GSEA as 294 295 described above, adjusting "Beta" value which was considered a ranking factor instead of log2 Fold Change. Significant suppressed GO BP terms were intersected with the corresponding 296 297 significant activated GSEA results of "Mitopure normalized over vehicle" comparison, resulting 298 to one common BP term, "Collagen Fibril Organization". Common core enrichment genes between the two instances of the particular term were further processed, and visualized as 299 follows: (a) For the RNA-seq dataset, bar plots of "Fold changes over vehicle" (see above for 300 301 definition) were plotted, while (b) the aging dataset was visualized as bar plots of Beta values.

302

#### **303 Quantitative real-time PCR (q-RT-QPCR)**

304 RNA from cells and reconstituted epidermis was extracted using TRIzol (Thermo Scientific, 305 15596026) and then transcribed to cDNA by the QuantiTect Reverse Transcription Kit (Qiagen, 306 205313) following the manufacturer's instructions. The q-RT-PCR reactions were performed 307 using the TaqPath ProAmp master mix (Applied biosystems, A30866) and the expression of 308 selected genes was analysed using the Quantstudio 6 flex (Life technologies) and following 309 TaqMan probes listed in Supplementary table 3. All quantitative polymerase chain reaction (PCR) 310 results were presented relative to the mean of housekeeping genes ( $\Delta\Delta$ Ct method). mRNA levels 311 were normalized over RPLP2 for gene expression for cell and tissue samples.

312

#### 313 **Reconstituted human epidermis**

Ten-day-old reconstructed human epidermis (RHE; batch 01015-587) were placed in proprietary maintenance medium (Bioalternatives). Topical application with a moisturizing cream with or without Mitopure at 1% was performed for 24 hours. The RHE were then rinsed in PBS and irradiated with UVB (+UVA) - 850 mJ/cm<sup>2</sup> (+ 6 J/cm<sup>2</sup>) using a SOL500 Sun Simulator equipped

318 with an H2 filter (Dr. Hönle, AG). After irradiation, the treatments were renewed and the RHE

incubated for 24 hours. In parallel, non-irradiated conditions were performed and kept in the dark

320 during the irradiation time. PGE2 released in the culture supernatants was measured using a

- 321 specific ELISA kit according to the supplier's instructions (Enzo Life Sciences, ADI-900-001).
- 322 All experimental conditions were performed in n=3.
- 323

#### 324 Statistical analysis

325 The mean values of raw data and calculated values were presented in bar charts with 95 %

326 confidence limits for each treatment and assessment time. A significance level of 0.05 (alpha)
327 was chosen for statistical analysis. Due to the proof-of-concept character of the study, no
328 adjustment for multiplicity was done. Pairwise comparison of treatments was done by paired t329 test on differences to baseline for each assessment time and treatment group. For visual and
330 imaging data pairwise comparison of treatments was done by Wilcoxon signed rank test on raw
331 data. The computation of the statistical data was carried out with commercially available
332 statistics software (SAS for Windows).

- 333
- 334
- 335
- 336
- 337

338

- 340
- 341
- 342
- 343

### 344 **Results**

#### 345 <u>Demographics</u>

346 For the *aging study 1*, a total of 55 participants were screened in the placebo-controlled, first aging study. Of them, n=48 middle aged women subject with mean age of  $58.6 \pm 6.6$  years were 347 348 randomized (Figure 1) in to two study arms with a split-face/arm study design with a lower dose 349 active group compared to placebo and a second higher dose active group compared to placebo. All participants completed the trial and there were no dropouts. Ethnicity of all participants was 350 Caucasian. In the *aging study* 2, n=108 middle-aged subjects with a mean age of  $55.4 \pm 6.6$  years 351 352 were randomized using a split face study design with a treatment side compared to an untreated 353 side. All subjects completed the study protocol (Supplementary Figure 1A). There were 29 males 354 (27 %) and 79 females (73 %) in the final analysis of which n=2 (2 %) were Black, 93 (86 %)355 were Caucasian, n=3 (3 %) East Asian, n=3 (3 %) Hispanic and n=7 (6 %) West Asian ethnicity. 356 In the UVB-mediated erythema trial (placebo-controlled, Photo-damage study), n=22 subjects 357 (10 male (48 %), 11 female (52 %) with mean age  $44.0 \pm 14.1$  years and Caucasian ethnicity) 358 were enrolled. There was one drop-out subject and n=21 subjects completed the study protocol 359 (Supplementary Figure 1B).

360

#### 361 <u>Safety</u>

362 In the *aging study 1*, no adverse reactions with any relationship to study products were reported 363 by any subject. In the aging study 2, four adverse reactions occurred across three subjects as 364 varying forms of skin irritation, including erythema, papules, itching and burning. Of the adverse reactions documented during the conduct of this study, all were classified as being of mild 365 366 severity (Supplementary Table 1). In all cases, subjects remained in the study and recovered 367 without sequelae. In the *photodamage trial*, two adverse reactions occurred in the form of skin 368 irritation with erythema in one subject. The reactions were of mild severity and resolved without 369 sequelae.

#### 371 Wrinkle reduction with 1% topical UA application

372 In the aging study 1, wrinkle reduction was measured after 2, and 8-weeks of test treatment 373 application (Fig. 2A). The UA 1% treatment group showed a significant reduction in wrinkle 374 depth at 8-weeks (p=0.04; Figure 2B) compared to the placebo treated side. UA at 0.5% did not 375 showed any significant effect compared to the Placebo (Supplementary Table 2). In the aging 376 study 2, UA at 1% was found to have a significant impact on reducing wrinkles (finer and 377 rougher skin structures computed as Ra and Rz, respectively) with the effect already manifesting after 2 weeks of application and maintained with 4 and 8-weeks of application, compared to the 378 379 untreated side (Supplementary Table 2). The effect was independent of timing of application and 380 matrix of the product applied, as the three products (day cream, night cream and serum) 381 containing 1% UA showed similar wrinkle reducing benefits (Figure 2C, day-cream; Figure 2D, 382 night-cream; data for serum are shown in Supplementary Table 3).

383

#### 384 Impact on Skin barrier and skin hydration

All subjects entering the skin aging studies had a healthy skin barrier and topical UA application showed no negative impact on skin barrier, with function remaining unchanged(Figure 2D). Daily application of the creams (day, night creams and serum) containing 1% UA significantly improved skin hydration after 2-weeks of use in comparison to pre-test treatment level. The observed improved skin hydration levels, as measured by skin capacitance, were maintained also after 8 weeks of application in comparison to the untreated side (Figure 2E, F, Supplementary Table 4).

392

#### 393 <u>Supportive biomarkers</u>

We investigated biological pathways impacted by topical UA application for a period of 8 weeks by performing RNA-seq transcriptomics of forearm skin biopsies from the *aging study I*. Gene set enrichment analysis (GSEA) was applied to identify significant pathways changed by UA comparing samples at the study end to baseline and normalizing results over vehicle. "Collagen fibril organization" was the molecular pathway most significantly activated by UA (Fig. 3A and

399 Suppl. Fig. 3A), with UA application also reducing gene sets related to chemokine response (Fig. 400 3A). We further studied which UA regulated pathways are involved in the natural skin aging process. Analysing a publicly available skin aging clinical study <sup>13</sup>, the "Collagen fibril 401 402 organization" was a common signature, both induced by UA and downregulated with skin aging 403 (Suppl. Fig. 3B). This gene set includes collagen genes encoding for fibrillar type I and III collagen (Fig. 3B), known to decline in skin with chronological aging <sup>14</sup>, photo-aging and 404 405 smoking<sup>15</sup>. UA also upregulated age-associated decline of genes involved in skin homeostasis. Among them, *EMILIN-1*, regulating 3D structure and elasticity <sup>16</sup> and *AEBP*, encoding for a 406 407 collagen-interacting protein required for optimal tissue repair <sup>17</sup> (Fig. 3B). These data provide 408 mechanistic insight into the positive impact of UA on wrinkle reduction, a process that is driven 409 by impaired collagen production and organization in the skin. The GSEA results reveals insights on the impact of UA on the dermis, the skin layer producing and secreting collagen. 410

To better understand the mechanisms of action of UA in dermal cells, we treated primary human dermal fibroblasts with UA at either 2.5  $\mu$ M or 10  $\mu$ M, or with vehicle, for 24 hours. Surprisingly, this short-term exposure to UA did not alter collagen gene expression (Suppl. Fig. 3C). However, it suppressed the expression of the gene involved in collagen degradation, Matrix Metalloproteinases (*MMP1*) (Fig. 3C). Moreover, UA induced a dose-dependent increase in the expression of the mitophagy genes *PARKIN* and *PINK1* and the autophagy genes *MAP1LC3* and *ULK1*, compared to vehicle-treated cells (Fig. 3C).

418 Human primary keratinocytes treated with UA or vehicle for 24 hours showed a similar gene 419 expression signature as dermal cells. UA led to a significant downregulation of both MMP1 and 420 the other key collagen degrading enzyme, MMP3 (Fig. 3D), and it upregulated autophagy and 421 mitophagy gene expression, as in dermal fibroblasts (Fig. 3D). Finally, we employed a model of 422 3D reconstituted human epidermis (RHE) applied daily with the UA 1% moisturizing cream for 423 3 days. No change was observed in MMP1 and MMP3 gene expression (Suppl. Fig 3D), however, 424 consistent with the data in primary cells, an early activation of mitophagy and autophagy genes 425 in RHE applied with UA compared to Vehicle in the RHE model (Fig. 3E).

#### 427 **Photodamage study**

#### 428 <u>Efficacy</u>

In the *photodamage study* all erythema (a\*)-values measured 24 hours after irradiation were higher than at baseline for all treatment codes, indicating the development of a sunburn on all the tested areas. The chromameter measurements showed significantly less skin redness (erythema) for 1 % UA treated group after UV exposure at the 1.6MED dose in comparison to the respective untreated area (-13%, p=0.02; Figure 4A), whereas neither the lower concentration with 0.5% (data not shown) nor the placebo showed a significant effect compared to the untreated control.

435

#### 436 Supportive Biomarkers

437 The clinical data from the *photodamage study* supports a protective effect of UA against UV irradiation induced skin damage. We used the RHE to investigate whether this was associated 438 439 with reduction in the reduction of detrimental inflammation generated by UV irradiation. RHE 440 were applied topically with either the basal topical formulation or a formulation containing UA 441 at 1%. After 24 hours of incubation, RHE tissues were exposed to UVB irradiation and then 442 incubated with the same topical formulations for an additional 24 hours. A group of RHE were left untreated and non-irradiated as negative controls. We measured the concentration of 443 prostaglandin G2 (PGE2) in the culture supernatant, as biomarker of inflammation. Irradiated 444 445 RHE showed significant increase in PGE2 release compared to non-irradiated tissues (Fig. 4B). 446 UA 1% application of irradiated RHE significantly reduced PGE2 levels, indicating an anti-447 inflammatory action or the active (Fig. 4B).

- 448
- 449
- 450
- 451
- 452
- 453
- 454
- 455

## 456 **Discussion**

457 Measures to protect against skin aging are essential for maintaining healthy, youthful-looking 458 skin and reducing the risk of skin damage and diseases. In this set of clinical studies, we showed 459 that topical application of skincare products containing UA significantly counteract both natural 460 intrinsic cellular aging and extrinsic photoaging. We performed three complementary randomized clinical studies to document both safety and efficacy of topically applied UA on the 461 462 skin of healthy adult subjects. Safety was confirmed by a lack of any serious side effects in all participants. In addition, a human-repeat insult patch test conducted (in n=109 subjects, 463 464 NCT05079607) prior to the start of these randomized trials revealed no irritant or sensitization 465 potential of UA on human skin (data not shown).

466

467 Efficacy of the active UA was observed both when applied alone in a basal topical cream 468 formulation (aging study 1) and when applied in a day, night cream or serum matrix with a calibrated dose of UA (aging study 2). Skin wrinkles are a hallmark of skin aging, especially on 469 470 facial skin and are known to contribute to the overall rate of aging by inducing oxidative stress 471 and via skin cells that acquire a pro-inflammatory state. Skin wrinkles in the crow's feet area 472 around the eyes were significantly reduced by an 8-week daily application of UA in multiple 473 skin cream matrices (basal cream formulation, a day-cream, a night cream and serum all 474 containing the same dose of 1% UA). This effect was visible as early as 2-weeks after topical 475 application in all the studies and with the different formulations (Supplementary Table xx). At 476 the molecular level, a hallmark of skin aging is the decline in content and organization of 477 collagen and the extracellular matrix, which provides structural support within the skin tissue. 478 Our data from unbiased skin biopsy RNA-sequencing, showed that topical application of 479 urolithin A increases the expression of the same collagen proteins down-regulated upon natural aging. Further mechanistic analysis in primary human cells and in 3D human skin models 480 481 revealed that short-term exposure to UA increased mitophagy and autophagy related genes. This is consistent with the molecular signature previously shown in several preclinical models and in 482 483 human clinical studies in the skeletal muscle. In the same skin models, UA also significantly 484 reduced expression of enzymes causing collagen degradation.

485 In addition to the protective effects of UA on intrinsic cellular aging, we provide evidence that 486 UA topical application counteracts photoaging. The exposure of excessive UVB radiation from 487 sun is linked to increased skin oxidative stress and an acceleration of skin tissue aging. UA was 488 already shown to protect against UVB-induced photoaging in 2D human dermal fibroblasts, through the activation of mitophagy  $^{18}$ . In the current report, we demonstrate for the first time in 489 humans that topically applied UA, in a randomized, double-blind trial, protects against UVB 490 491 exposed skin, with effects observed following a little as 24-hours after UV exposure that was 492 equivalent to a moderate sunburn. We demonstrated the active UA doses required to significantly 493 reduce UVB irradiation induced erythema formation. Employing a 3D human skin model to 494 investigate mechanistic benefits of UA, we observed a reduced production of prostaglandin E2 495 (PGE2), a pro-inflammatory molecule induced by UV irradiation.

496

497 Compared to UA, other actives employed to counter skin aging have either a less favourable 498 safety profile or more limited range of beneficial effects. Retinol is a commonly used active 499 known to increase collagen production, reduce fine lines, wrinkles and to improve photoaging 500 <sup>5,19</sup>. However, retinol increases cell turnover in skin, which results in peeling and dry and flaky 501 effect on skin. It has been shown to cause a dose dependent irritation and erythema with repeated 502 use<sup>20</sup>. In addition, retinol gets degraded on exposure to light and air <sup>21</sup>.

503

504 There are limited interventions to counteract the effects of both skin natural aging that leads to 505 wrinkle reduction and photoaging, without undesirable side effects. In these randomized clinical 506 studies, across ~180 subjects, topical application of the natural compound UA was shown to be 507 safe and achieved statistically significant improvement in the signs of both intrinsic aging 508 (wrinkle reduction) and extrinsic aging, i.e., UVB-induced photodamage (erythema) in healthy 509 subjects. The benefits were associated with the modulation of collagen and mitochondrial related 510 pathways that contribute to the skin aging processes. Taken together, these results show that UA 511 is a safe and effective natural intervention to counteract skin aging.

- 512
- 513
- 514

## 515 Author Contributions

- 516 A.S., C.R. and D.D. contributed to the design of the study. A.S. oversaw the clinical study
- 517 conduct and operations. N.H. and M.B. coordinated on-site clinical study execution and sample
- 518 collection as Principal investigators; D.D. oversaw the biomarkers analyses. A.M.F. performed
- sample processing, and cell-based experiments. A.F., D.D. analyzed the ex-vivo data. D.K.,
- 520 performed all bioinformatic analyses. D.D., J.F., C.R., and A.S. interpreted the data and wrote
- 521 the manuscript, with the help of the other co-authors. All authors reviewed the manuscript.
- 522

## 523 Conflict of Interest Disclosures

- 524 The authors declare the following competing interests: D.D., A.M.F., J.F., C.R. and A.S., are
- 525 employees of Amazentis SA, who is the sponsor of this clinical study.
- 526

## 527 Acknowledgement

The authors would like to thank all the study participants for their involvement in the different
clinical studies.
<liclinical studi

## 541 Figure Legends

Figure 1. CONSORT Diagram of *Aging Study 1* 55 Participants were screened in the placebocontrolled, first aging study of which n=48 middle aged women subject with mean age of  $58.6 \pm$ 6.6 years were randomized to two study arms with a split-face/arm study design with a lower dose active group compared to placebo and a second higher dose active group compared to placebo. Skin biopsies were conducted on the volar forearm in adjacent areas at the start and end of the 8-week intervention. All participants completed the trial and were included in the final analysis.

549

#### 550 Figure 2. Topical application of UA leads to wrinkle reduction effect

551 UA 1% topically applied in a basic skin cream (A) in the *aging study 1* or in a more defined

552 matrix of day (**B**) and night (**C**) skin cream formulations from the *aging study 2*, exhibited

significant anti-wrinkle effects in middle-aged subjects with moderate facial wrinkles after 8-

554 weeks of topical application (p<0.05). Skin barrier function remained healthy and unchanged

555 over the course of the *aging study 1* (**D**). Skin hydration was improved upon topical application

556 of different UA containing creams in *aging study 2* (**E**, **F**).

557

#### 558 Figure 3. UA positively impacts biomarkers associated with improved skin health (A)

559 GSEA results from RNA-seq in skin biopsies from *aging study 1* showing the most significant

560 Gene Ontology Biological Processes (GO-BP) pathways that are significantly enriched in UA

561 compared to vehicle. Terms with positive and negative normalized enrichment scores (NES), are

562 categorized as "activated" and "suppressed", respectively. Pathways are sorted by gene ratio, dot

sizes scaled by the number of core enriched genes, and dot color reflects the statistical

significance of the enrichment (Benjamini-Hochberg-adjusted p-value, P-adj). (**B**) Bar plot

showing increased expression in core genes of the "Collagen fibril organization" pathway in skin

566 biopsies exposed to UA compared to the vehicle group (top). Bar plot of Aging Beta value for

same genes derived from the skin aging trial (bottom). Only common core enriched genes

between UA and skin aging dataset are shown. (C-D) Expression of genes encoding for collagen

- 569 degrading enzymes (*MMP1*, *MMP3*) and autophagy/mitophagy proteins (*PINK1*, *PARK2*,
- 570 SQSTM1, ULK1) in human dermal fibroblasts (C) and human keratinocytes (D) treated for 24

- 571 hours with DMSO or the indicated doses of UA. (E) Expression of genes encoding for
- autophagy/mitophagy proteins (PINK1, PARK2, SQSTM1, ULK1) in human reconstituted
- 573 epidermis after daily application for 72 hours of Vehicle or UA 1% containing moisturizers. Data
- 574 expressed as Fold change over Vehicle +/- sem. \*p< 0.05; \*\*P < 0.01; \*\*\*P < 0.005; \*\*\*P < 0.005
- 575 0.001 One-Way ANOVA.
- 576
- Figure 4. (A). (B) Levels of prostaglandin E2 (PGE2) secreted in the media of 3D reconstituted
  human epidermis in the indicated experimental conditions. Data expressed as Fold change over
  Vehicle +/- sem. \*p< 0.05; \*\*\*P < 0.005. One-Way ANOVA.</li>
- 580
- 581

## 582 Supplementary Figure Legends

- 583 Supplementary Figure 1. CONSORT Flow Diagram for (A) Aging Study 2 and (B) UVB-
- 584 induced Erythema, *Photodamage Trial*
- 585

# Supplementary Figure 2. Impact of Mitopure on biomarkers associated with improved skin health

588 (A) Heatmap of log2 fold changes from core enriched genes of the "Collagen fibril organization" 589 pathway comparing end of study to baseline, in UA skin biopsies after normalization over 590 vehicle controls. Only subjects present in both visits and both treatments are considered in 591 visualization. Rows (genes) were hierarchically clustered with a Euclidean distance metric using 592 complete linkage. (B) Normalized enrichment score (NES) of "Collagen fibril organization" 593 pathway for UA normalized over vehicle comparison and for the "aging" dataset. The 594 significance level of the BP enrichment for each comparison/dataset is denoted accordingly. (C) 595 Expression of the gene encoding for Collagen Type I Alpha 1 Chain (COL1A1) in human dermal 596 fibroblasts treated for 24 hours with DMSO or the indicated doses of Mitopure. (D) Expression 597 of genes encoding for collagen degrading enzymes (MMP1, MMP3) in human reconstituted epidermis after daily application for 72 hours of Vehicle or Mitopure 1% containing moisturizer. 598 599 Data expressed as Fold change over Vehicle +/- sem.

1. Pandel R, Poljšak B, Godic A, Dahmane R. Skin photoaging and the role of antioxidants in

## 600 **References**

602		its prevention. ISRN Dermatol. 2013;2013:930164. doi:10.1155/2013/930164
603 604	2.	Baumann L. Skin ageing and its treatment. <i>J Pathol</i> . 2007;211(2):241-251. doi:10.1002/path.2098
605 606	3.	Farage MA, Miller KW, Elsner P, Maibach HI. Structural characteristics of the aging skin: a review. <i>Cutan Ocul Toxicol</i> . 2007;26(4):343-357. doi:10.1080/15569520701622951
607 608	4.	Pilkington SM, Bulfone-Paus S, Griffiths CEM, Watson REB. Inflammaging and the Skin. <i>J</i> <i>Invest Dermatol</i> . 2021;141(4S):1087-1095. doi:10.1016/j.jid.2020.11.006
609 610	5.	Kafi R, Kwak HSR, Schumacher WE, et al. Improvement of naturally aged skin with vitamin A (retinol). <i>Arch Dermatol</i> . 2007;143(5):606-612. doi:10.1001/archderm.143.5.606
611 612	6.	Mariwalla K. SUPPLEMENT ARTICLE: Effectiveness of Retinol for Skin Health. <i>J Drugs Dermatol</i> . 2022;21(7):s3. doi:10.36849/JDD.0722
613 614 615	7.	D'Amico D, Andreux PA, Valdés P, Singh A, Rinsch C, Auwerx J. Impact of the Natural Compound Urolithin A on Health, Disease, and Aging. <i>Trends Mol Med</i> . 2021;27(7):687- 699. doi:10.1016/j.molmed.2021.04.009
616 617 618	8.	Liu S, D'Amico D, Shankland E, et al. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. <i>JAMA</i> <i>Netw Open</i> . 2022;5(1):e2144279. doi:10.1001/jamanetworkopen.2021.44279
619 620 621	9.	Singh A, D'Amico D, Andreux PA, et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. <i>Cell Rep Med</i> . 2022;3(5):100633. doi:10.1016/j.xcrm.2022.100633
622 623 624	10.	Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge- based approach for interpreting genome-wide expression profiles. <i>Proc Natl Acad Sci U S A</i> . 2005;102(43):15545-15550. doi:10.1073/pnas.0506580102

625	11. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R Package for Comparing Biological
626	Themes Among Gene Clusters. OMICS: A Journal of Integrative Biology. 2012;16(5):284-
627	287. doi:10.1089/omi.2011.0118
628	12. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology.
629	The Gene Ontology Consortium. Nat Genet. 2000;25(1):25-29. doi:10.1038/75556
630	13. Glass D, Viñuela A, Davies MN, et al. Gene expression changes with age in skin, adipose
631	tissue, blood and brain. Genome Biol. 2013;14(7):R75. doi:10.1186/gb-2013-14-7-r75
632	14. Varani J, Dame MK, Rittie L, et al. Decreased collagen production in chronologically aged
633	skin: roles of age-dependent alteration in fibroblast function and defective mechanical
634	stimulation. Am J Pathol. 2006;168(6):1861-1868. doi:10.2353/ajpath.2006.051302
635	15. Knuutinen A, Kokkonen N, Risteli J, et al. Smoking affects collagen synthesis and
636	extracellular matrix turnover in human skin. Br J Dermatol. 2002;146(4):588-594.
637	doi:10.1046/j.1365-2133.2002.04694.x
638	16. Fitoussi R, Beauchef G, Guéré C, André N, Vié K. Localization, fate and interactions of
639	Emilin-1 in human skin. Int J Cosmet Sci. 2019;41(2):183-193. doi:10.1111/ics.12524
640	17. Blackburn PR, Xu Z, Tumelty KE, et al. Bi-allelic Alterations in AEBP1 Lead to Defective
641	Collagen Assembly and Connective Tissue Structure Resulting in a Variant of Ehlers-Danlos
642	Syndrome. Am J Hum Genet. 2018;102(4):696-705. doi:10.1016/j.ajhg.2018.02.018
643	18. Liu W, Yan F, Xu Z, et al. Urolithin A protects human dermal fibroblasts from UVA-
644	induced photoaging through NRF2 activation and mitophagy. J Photochem Photobiol B.
645	2022;232:112462. doi:10.1016/j.jphotobiol.2022.112462
646	19. Pisetpackdeekul P, Supmuang P, Pan-In P, et al. Proretinal nanoparticles: stability, release,
647	efficacy, and irritation. Int J Nanomedicine. 2016;11:3277-3286. doi:10.2147/IJN.S111748
648	20. Milosheska D, Roškar R. Use of Retinoids in Topical Antiaging Treatments: A Focused
649	Review of Clinical Evidence for Conventional and Nanoformulations. Adv Ther.
650	2022;39(12):5351-5375. doi:10.1007/s12325-022-02319-7
	23

- 651 21. Mukherjee S, Date A, Patravale V, Korting HC, Roeder A, Weindl G. Retinoids in the
- treatment of skin aging: an overview of clinical efficacy and safety. *Clin Interv Aging*.
- 653 2006;1(4):327-348. doi:10.2147/ciia.2006.1.4.327
- 654 22. Bhagavan HN, Chopra RK. Coenzyme Q10: absorption, tissue uptake, metabolism and
- 655 pharmacokinetics. *Free Radic Res.* 2006;40(5):445-453. doi:10.1080/10715760600617843
- 656 23. Inui M, Ooe M, Fujii K, Matsunaka H, Yoshida M, Ichihashi M. Mechanisms of inhibitory
- effects of CoQ10 on UVB-induced wrinkle formation in vitro and in vivo. *Biofactors*.
- 658 2008;32(1-4):237-243. doi:10.1002/biof.5520320128
- 659



Figure 1





Day Cream (UA 1%)

Untreated

Night Cream (UA 1%) Untreated



Α

С

Gene expression

D

Gene expression

(Fold change)

Skin biopsies enriched pathways Urolithin A normalized over vehicle





degradation





0.3 0.4 0.5

0.100 0.075 0.050 0.025 0.000

Vehicle

UA 2.5 μM UA 10 μM

Genes activated with UA



Genes suppressed with aging



Ε





Mitophagy/Autophagy





